Fortis Healthcare stock
FORTIS.NSNSEFortis Healthcare Limited, HealthcareISIN INE061F01013
52Score 52 out of 100, Neutral
Price and trend
44 / 100
Price history
−22% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is 25% below its 52-week high. Largest decline in 20 years: 58% (January 2008 to October 2008).
Chart figures for advanced users
- SMA 50$8.62
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.47
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.58
- The lowest closing price of the last twelve months.
- Resistance$10.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Fortis Healthcare Limited belongs to the Medical (Care Facilities) industry (India) and, with a market value of $6.1B, is number 15 of 57 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $970.18M (up 17.2% year on year) and earnings of $110.73M (up 34.6%).
- For fiscal 2027, analysts expect on average revenue of $1.13B (up 16.8%) and adjusted earnings per share of $0.18 (up 19.8%).
Show more
- MEQIRI Score 52 out of 100 (Neutral): rank 357 of 702 in Healthcare, median 53.
- The P/E is 55.2 (Medical (Care Facilities) median 55.2, own median of recent years 54.1).
- Our model puts fair value at $7.66, with the price 5% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 25% a year through 2029 (estimates from 15 analysts).Growth 70
Weaknesses
- Margin fallingOperating margin 17.9%, average of the prior years 52.4% (to 2025).Profitability 61
Its standout strength is growth, while valuation and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 53 to 52.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $5.89 and expensive above $10.95 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $7.25 (cash-flow model) and $8.07 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $7.06, at 11.6% it would be $8.53.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (55.2).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.5% on the twelve months before. Revenue has grown strongly since 2007, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 37%, operating 18%, net 11%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 14 Feb 2027in 93 days
- Last reported
- 5 Nov 2026EPS reported $0.04 (expected $0.05)below expectations
Analyst estimates
Earnings estimates have barely changed since 27 Oct 2026.
- Earnings per share
- $0.180.0%
- Revenue
- $1.13B0.0%
- Earnings per share
- $0.240.0%
- Revenue
- $1.3B0.0%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Fortis Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Ensign GroupENSG $10.88B66
- Max Healthcare InstituteMAXHEALTH.NS $9.79B54
- PACS GroupPACS $7.62B66
- ChemedCHE $7.16B75
- Concentra Group Holdings ParentCON $5.44B69
- LifeStance Health GroupLFST $5.38B57
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.44B35
ETFs that hold Fortis Healthcare
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.30% | 0.65% | €4.98B |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.21% | 0.60% | €31.52M |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.05% | 0.20% | €7.14B |
Show 5 more
| iShares MSCI EM UCITS ETF USD (Dist)IQQE | 0.04% | 0.18% | €8.51B |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.04% | 0.18% | €9.52B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.04% | 0.18% | €37.98B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.03% | 0.18% | €5.26B |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.02% | 0.25% | €661.06M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 8 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.